Trefoil Therapeutics is a technology company.
Trefoil Therapeutics has raised $28.0M across 1 funding round.
Key people at Trefoil Therapeutics.
Trefoil Therapeutics has raised $28.0M in total across 1 funding round.
Key people at Trefoil Therapeutics.
Trefoil Therapeutics has raised $28.0M in total across 1 funding round.
Trefoil Therapeutics's investors include 5AM Ventures, Canaan Partners, Hatteras Venture Partners.
Trefoil Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies to restore sight for individuals suffering from corneal diseases. Their lead product, TTHX1114, is an engineered Fibroblast Growth Factor (FGF1) designed to promote corneal regeneration and treat various corneal conditions through both intracameral and topical formulations. The company serves patients with limited treatment options for corneal diseases, aiming to improve vision and quality of life. Trefoil has demonstrated growth momentum with positive Phase 2 clinical trial results for TTHX1114, particularly in treating Fuchs Endothelial Corneal Dystrophy, signaling progress toward regulatory approval and broader clinical adoption[1][2][4].
Trefoil was founded by a team with over 100 years of combined experience in ophthalmic drug development, leveraging deep scientific and clinical expertise in corneal biology and regenerative medicine. The idea emerged from the need to address the lack of effective treatments for corneal endothelial diseases, which can lead to vision loss. Early traction includes significant funding exceeding $10 million and collaborations with institutions such as the NIH and the U.S. Department of Defense, underscoring confidence in their therapeutic approach[1][3][4].
Trefoil is positioned at the intersection of regenerative medicine and ophthalmology, riding the trend of biologics and growth factor therapies to address unmet medical needs in eye care. The timing is critical as the aging global population increases the prevalence of corneal diseases, and current treatments like corneal transplants face limitations such as donor shortages and surgical risks. Trefoil’s approach could reduce reliance on transplants and transform treatment paradigms, influencing the broader ecosystem by advancing regenerative therapies for ocular diseases[1][3].
Looking ahead, Trefoil Therapeutics is poised to advance TTHX1114 through late-stage clinical trials and toward regulatory approval, potentially becoming a leader in corneal regenerative therapies. Trends such as personalized medicine, biologics, and increased investment in ophthalmic innovation will shape their journey. Their influence may expand as they validate their platform and explore additional indications or delivery methods, contributing to a shift in how corneal diseases are treated globally.
Trefoil’s commitment to restoring sight through cutting-edge science ties back to their foundational mission, promising to impact millions of patients with vision impairment due to corneal disease.
Trefoil Therapeutics has raised $28.0M across 1 funding round. Most recently, it raised $28.0M Series A in November 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2021 | $28.0M Series A | 5AM Ventures, Canaan Partners, Hatteras Venture Partners |
